StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$44.89−1.96 (-4.18%)

Close on Nov 18, 2026Market cap $3.29BP/E –Yield –

Enliven Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for Enliven Therapeutics

Enliven Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Enliven Therapeutics figures

See a number that looks wrong?